Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Qiu Li, Chunlei Jin, Shanzhi Gu et al.|Journal of Clinical Oncology|2020

Cited by 36